Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117241

Cellular markers that distinguish the phases of hemangioma during infancy and childhood.

K Takahashi, J B Mulliken, H P Kozakewich, R A Rogers, J Folkman, and R A Ezekowitz

Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts 02115.

Find articles by Takahashi, K. in: JCI | PubMed | Google Scholar

Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts 02115.

Find articles by Mulliken, J. in: JCI | PubMed | Google Scholar

Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts 02115.

Find articles by Kozakewich, H. in: JCI | PubMed | Google Scholar

Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts 02115.

Find articles by Rogers, R. in: JCI | PubMed | Google Scholar

Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts 02115.

Find articles by Folkman, J. in: JCI | PubMed | Google Scholar

Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts 02115.

Find articles by Ezekowitz, R. in: JCI | PubMed | Google Scholar

Published June 1, 1994 - More info

Published in Volume 93, Issue 6 on June 1, 1994
J Clin Invest. 1994;93(6):2357–2364. https://doi.org/10.1172/JCI117241.
© 1994 The American Society for Clinical Investigation
Published June 1, 1994 - Version history
View PDF
Abstract

Hemangiomas, localized tumors of blood vessels, appear in approximately 10-12% of Caucasian infants. These lesions are characterized by a rapid proliferation of capillaries for the first year (proliferating phase), followed by slow, inevitable, regression of the tumor over the ensuing 1-5 yr (involuting phase), and continual improvement until 6-12 yr of age (involuted phase). To delineate the clinically observed growth phases of hemangiomas at a cellular level, we undertook an immunohistochemical analysis using nine independent markers. The proliferating phase was defined by high expression of proliferating cell nuclear antigen, type IV collagenase, and vascular endothelial growth factor. Elevated expression of the tissue inhibitor of metalloproteinase, TIMP 1, an inhibitor of new blood vessel formation, was observed exclusively in the involuting phase. High expression of basic fibroblast growth factor (bFGF) and urokinase was present in the proliferating and involuting phases. There was coexpression of bFGF and endothelial phenotypic markers CD31 and von Willebrand factor in the proliferating phase. These results provide an objective basis for staging hemangiomas and may be used to evaluate pharmacological agents, such as corticosteroids and interferon alfa-2a, which accelerate regression of hemangiomas. By contrast, vascular malformations do not express proliferating cell nuclear antigen, vascular endothelial growth factor, bFGF, type IV collagenase, and urokinase. These data demonstrate immunohistochemical differences between proliferating hemangiomas and vascular malformations which reflect the biological distinctions between these vascular lesions.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2357
page 2357
icon of scanned page 2358
page 2358
icon of scanned page 2359
page 2359
icon of scanned page 2360
page 2360
icon of scanned page 2361
page 2361
icon of scanned page 2362
page 2362
icon of scanned page 2363
page 2363
icon of scanned page 2364
page 2364
Version history
  • Version 1 (June 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts